Alpine Tooth Fungus

Metadata

Regulatory Status

European Union and Member States

• Conservation status: Hericium alpestre (H. flagellum) is red-listed in most European countries. All European Hericium species are considered rare and threatened. The species serves as a biological indicator of natural old-growth forests and high conservation value areas.
• Habitat dependency: Strongly host-dependent on coniferous wood, especially silver fir (Abies alba). Over 57% of recorded specimens were found in high conservation value areas on fallen trunks of silver fir trees. The species’ range is closely tied to the distribution of Abies alba in montane areas across Europe.
• Legal protection: Protected under various national conservation laws in European countries. Collection from the wild is prohibited or restricted in most jurisdictions where it occurs.
• Novel food: No novel food authorization exists for H. alpestre extracts or supplements. The species has not been commercially available as a food in the EU market.

Geographic Distribution

• Range: Montane forests of Central and Southern Europe, including the Alps, Carpathians, Pyrenees, and mountainous regions of Poland, Germany, Italy, France, Austria, Switzerland, and the Balkans. Recently also documented from Scandinavia.
• Habitat: Found on newly fallen trunks and stumps of fir species, particularly silver fir (Abies alba). Occasionally reported on other conifers including spruce (Picea) and larch (Larix). Requires late-successional or old-growth forest conditions with abundant coarse woody debris.

China, Japan, and United States

• Status: H. alpestre is not native to East Asia or North America. The related species H. erinaceus (Lion’s Mane) is the principal medicinal species in these regions. H. americanum and H. coralloides occupy comparable ecological niches in North American forests.

Conditions & Indications

Primary Indications (Preclinical Evidence, Informed by Genus-Level Research)

• Neuroprotection and NGF stimulation — Mycelial cultures of H. flagellum (H. alpestre) produce erinacines A, B, C, E, and F, all of which are established stimulators of nerve growth factor (NGF) synthesis. Rupcic et al. (2018) demonstrated that the novel erinacine Z1 also increases NGF expression in 1321N1 astrocytic cells, while erinacine C was confirmed to increase both NGF and BDNF (brain-derived neurotrophic factor) expression. NGF and BDNF are essential neurotrophins for neuronal survival, differentiation, synaptic plasticity, and repair of damaged neural tissue.
• Anticancer activity — Erinacine Z2, isolated from H. flagellum mycelial cultures, exhibited potent cytotoxicity against HL-60 promyelocytic leukemia cells with an IC50 of 0.5 micromolar. Erinacine Z1 was also cytotoxic but 18-fold less potent (IC50 8.9 micromolar). These sub-micromolar IC50 values place erinacine Z2 among the more potent naturally occurring cytotoxic compounds from the Hericium genus.

Secondary Indications (Inferred from Genus-Level Evidence)

• Neurodegenerative disease support — Based on the demonstrated erinacine profile shared with H. erinaceus, H. alpestre extracts would be expected to possess similar neuroprotective potential in neurodegenerative conditions. For H. erinaceus, erinacines have shown benefit in preclinical models of Alzheimer’s disease, Parkinson’s disease, ischemic stroke, and depression through NGF and BDNF upregulation, anti-neuroinflammatory activity, and neuronal cell death prevention. [UNCERTAIN — species-specific studies in disease models have not been conducted for H. alpestre.]
• Immunomodulation — All Hericium species produce beta-glucan polysaccharides with immunomodulatory properties. While species-specific immunological studies on H. alpestre are lacking, the genus-level evidence strongly supports immunomodulatory potential through Dectin-1-mediated innate immune activation. [NEEDS-RESEARCH]
• Antioxidant activity — Hericium species generally exhibit antioxidant activity through phenolic compounds and polysaccharides. H. alpestre extracts have been reported to exhibit antioxidant activity, though detailed species-specific studies are limited. [NEEDS-RESEARCH]

Emerging/Preclinical Indications

• BDNF enhancement — Erinacine C, produced by both H. alpestre and H. erinaceus, increases BDNF expression. BDNF is critical for hippocampal neurogenesis, memory consolidation, and mood regulation. BDNF deficiency is implicated in depression, anxiety, and cognitive decline. [UNCERTAIN — BDNF effects specifically measured in H. alpestre-derived erinacine C; broader clinical implications extrapolated from H. erinaceus research.]
• Novel compound discovery — The identification of erinacines Z1 and Z2 suggests that H. alpestre may produce additional undiscovered cyathane diterpenoids not found in H. erinaceus. Further metabolomic profiling could reveal a distinctive pharmacological niche for this species. [NEEDS-RESEARCH]

Mechanism of Action

Primary Mechanisms

1. Erinacine-mediated NGF synthesis stimulation Cyathane diterpenoids (erinacines) produced in H. alpestre mycelium cross the blood-brain barrier and stimulate the synthesis and secretion of nerve growth factor (NGF) from astrocytes. The mechanism involves induction of NGF mRNA transcription, leading to increased NGF protein production and release into the extracellular space. NGF then binds to TrkA receptors on cholinergic neurons, activating downstream signaling cascades including the Ras-MAPK/ERK pathway and the PI3K-Akt pathway, which promote neuronal survival, axonal growth, and synaptic plasticity. Erinacines A, B, C, E, and F — all confirmed in H. alpestre mycelial cultures — are established NGF inducers. The novel erinacine Z1 was additionally shown to increase NGF expression, expanding the number of known NGF-inducing metabolites from this species.

2. BDNF upregulation by erinacine C Erinacine C, confirmed in H. alpestre mycelial cultures, upregulates brain-derived neurotrophic factor (BDNF) expression. BDNF binds to TrkB receptors and activates similar but distinct downstream cascades from NGF, promoting neurogenesis in the hippocampal dentate gyrus, enhancing long-term potentiation (the cellular basis of learning and memory), and supporting survival of dopaminergic, serotonergic, and GABAergic neurons. The dual NGF/BDNF induction by erinacine C is particularly significant for broad neuroprotective coverage.

3. Direct cytotoxicity via erinacine Z2 Erinacine Z2, unique to H. alpestre/flagellum, exhibits potent direct cytotoxicity against HL-60 leukemia cells (IC50 0.5 micromolar). While the precise molecular target is not yet elucidated, cyathane diterpenoids from Hericium species have been shown to induce apoptosis through mitochondrial pathway activation, caspase cascade initiation, and cell cycle arrest. The sub-micromolar potency of erinacine Z2 suggests high-affinity interaction with a specific molecular target, warranting further mechanistic investigation.

Secondary Mechanisms

• Beta-glucan immunomodulation: Like all Hericium species, H. alpestre produces beta-glucan polysaccharides that activate innate immune cells through Dectin-1 and complement receptor 3 (CR3), enhancing macrophage phagocytosis, NK cell activity, and cytokine production.
• Antioxidant defense: Phenolic compounds and polysaccharides contribute to reactive oxygen species scavenging and enhancement of endogenous antioxidant enzyme activity (SOD, catalase, glutathione peroxidase), reducing oxidative damage to neurons and other tissues.
• Anti-neuroinflammatory activity: Based on genus-level evidence from H. erinaceus, erinacines are expected to suppress neuroinflammatory cascades by inhibiting microglial activation and reducing pro-inflammatory cytokine production (TNF-alpha, IL-1-beta, IL-6) in the central nervous system.

Key Active Compounds

Clinical Evidence Summary

No human clinical trials have been conducted with Hericium alpestre (H. flagellum). The clinical evidence base for the Hericium genus comes almost entirely from studies on H. erinaceus (Lion’s Mane), and the pharmacological characterization of H. alpestre comes from a small number of laboratory studies.

Species-Specific Studies on H. alpestre/flagellum

Relevant H. erinaceus Clinical Trials (Genus-Level Evidence)

Evidence Limitations

• Only one study (Rupcic et al., 2018) has directly characterized the bioactive compounds of H. alpestre/flagellum in detail. This is the cornerstone of the species-specific evidence base.
• No human clinical trials have been conducted with H. alpestre preparations.
• The pharmacological inference from H. erinaceus, while supported by shared metabolite profiles, has not been experimentally validated through comparative in vivo studies.
• The novel erinacines Z1 and Z2 have been characterized only in vitro. Their in vivo pharmacokinetics, blood-brain barrier penetration, and therapeutic efficacy are unknown.
• The conservation status of H. alpestre severely limits availability of wild material for research. All future research must rely on cultivated material.
• The cytotoxicity data (HL-60 IC50 values) represent in vitro cancer cell line activity and cannot be directly translated to clinical anticancer efficacy.
• The relationship between erinacine Z1/Z2 and the known erinacines regarding NGF/BDNF potency requires further comparative study.

Safety Profile

General Assessment

H. alpestre is edible and belongs to a genus with a long history of safe culinary and medicinal use. All Hericium species are considered non-toxic edible mushrooms. However, species-specific safety data for H. alpestre are essentially absent. Safety inferences are drawn from the closely related H. erinaceus, which has been consumed as food and medicine for centuries and has been evaluated in multiple human clinical trials without significant adverse events.

Contraindications

• Known mushroom allergy: Individuals with allergies to Hericium species or other basidiomycete mushrooms should avoid H. alpestre.
• Pregnancy and lactation: Insufficient safety data. No human studies exist. Avoid until safety is established.

Drug Interactions

• Theoretical — anticoagulants: H. erinaceus has shown mild antiplatelet activity in some studies. This effect has not been studied in H. alpestre, but caution is warranted by analogy.
• Theoretical — immunosuppressants: Beta-glucan immunomodulatory activity could theoretically interfere with immunosuppressive therapy.
• Theoretical — antidiabetic agents: H. erinaceus has shown hypoglycemic effects in some preclinical studies. If H. alpestre shares this property, additive hypoglycemia risk with antidiabetic medications is possible.

Side Effects

• From H. erinaceus (genus-level inference): Clinical trials of H. erinaceus report mild, transient gastrointestinal effects (nausea, abdominal discomfort) in a minority of participants. Skin itching has been reported rarely, potentially related to increased NGF activity (NGF promotes sensory nerve sensitivity).
• From H. alpestre: No species-specific adverse event data exist.

Conservation and Ethical Considerations

• Wild harvest of H. alpestre is ecologically irresponsible and legally prohibited in most jurisdictions due to the species’ rare and threatened status.
• Any future medicinal or supplement development must rely exclusively on cultivated material.
• Mycelial cultivation in submerged or solid-state culture is the most practical approach, as it produces the erinacines that are the primary compounds of interest and does not require the formation of fruiting bodies on host wood.

Clinical Dosage

No Established Therapeutic Doses

• No human therapeutic doses have been established for any H. alpestre preparation.
• The species is not currently commercially available as a food or supplement.

Inferred from H. erinaceus Clinical Trials

• Dried fruiting body powder (H. erinaceus): 3 g/day (Mori et al., 2009 — cognitive improvement in mild cognitive impairment)
• Erinacine A-enriched mycelium extract (H. erinaceus): Various doses used in clinical trials, typically containing standardized erinacine A content
• Note: These doses are for H. erinaceus and cannot be directly applied to H. alpestre without species-specific dosing studies, though the shared metabolite profile suggests comparable dose ranges may be appropriate.

Cultivation Notes

• Mycelial cultivation on barley bran has been identified as the optimal substrate for H. alpestre biomass production.
• Submerged liquid cultivation is feasible and produces erinacines, including the novel Z1 and Z2 compounds.
• Erinacine P is produced in much larger quantities than other erinacines in submerged culture, serving as a precursor for semi-synthetic production of erinacines A and B.
• Commercial-scale cultivation has not been developed for H. alpestre, though the cultivation protocols established for H. erinaceus provide a foundation.

Sources

• Rupcic Z, Rascher M, Kanaki S, et al. Two New Cyathane Diterpenoids from Mycelial Cultures of the Medicinal Mushroom Hericium erinaceus and the Rare Species, Hericium flagellum. Int J Mol Sci. 2018;19(3):740
• Thongbai B, Rapior S, Hyde KD, Wittstein K, Stadler M. Hericium erinaceus, an amazing medicinal mushroom. Mycol Progress. 2015;14:91
• Szulczewski JW, et al. Distribution and ecological traits of a rare and threatened fungus Hericium flagellum in Poland with the prediction of its potential occurrence in Europe. Fungal Ecol. 2020;47:100961
• Kujawska A, et al. First record of Hericium flagellum (Basidiomycota) from the “Olbina” nature reserve in Wielkopolska Voivodship, Poland. Acta Mycol. 2019;54(2):1133
• Schueffler A, et al. Polysorbate 80 Differentially Impacts Erinacine Production Profiles in Submerged Cultures of Hericium. Molecules. 2025;30(13):2823
• Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T. Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytother Res. 2009;23(3):367-372
• Li IC, Chang HH, Lin CH, et al. Prevention of Early Alzheimer’s Disease by Erinacine A-Enriched Hericium erinaceus Mycelia Pilot Double-Blind Placebo-Controlled Study. Front Aging Neurosci. 2020;12:155
• Saitsu Y, Nishide A, Kikushima K, Shimizu K, Ohnuki K. Improvement of cognitive functions by oral intake of Hericium erinaceus. Biomed Res. 2019;40(4):125-131
• Trovato Salinaro A, et al. Unveiling the Chemical Composition and Biofunctionality of Hericium spp. Fungi: A Comprehensive Overview. Nutrients. 2024;16(9):1292
• Li QZ, et al. The ethnopharmacology, phytochemistry and pharmacology of the genus Hericium. J Ethnopharmacol. 2024;320:117334
• IUCN Red List. Hericium alpestre. Species view 224021. Available at: https://redlist.info/iucn/species_view/224021/

Connections

• Lion’s Mane — The most closely related well-studied species. H. erinaceus is the primary source of clinical evidence for erinacine-based neuroprotection. H. alpestre shares the same core erinacine profile (A, B, C, E, F) but produces two unique novel cyathane diterpenoids (Z1, Z2) not found in H. erinaceus. The metabolite profiles are highly similar, supporting pharmacological inference from H. erinaceus to H. alpestre, but the unique compounds merit independent investigation. H. erinaceus grows on deciduous hardwoods, while H. alpestre is restricted to conifers (especially silver fir).
• Coral Tooth — Another Hericium species found in European forests, though it grows on deciduous wood rather than conifers. H. coralloides also produces erinacines and has demonstrated neuroprotective properties. Together with H. alpestre and H. erinaceus, these species represent a neuroprotective genus.
• Bear’s Head Tooth — The North American Hericium species most similar to H. alpestre in morphology. H. americanum grows on deciduous hardwoods and has been included in comparative erinacine production studies alongside H. flagellum.
• Reishi — As the most studied immunomodulatory and neuroprotective mushroom, reishi provides pharmacological context for Hericium genus research. The combination of Hericium (NGF/BDNF stimulation) and reishi (adaptogenic, immune modulation) is a common integrative neurology protocol, and H. alpestre’s unique erinacines could expand this application.